Arlington Capital Partners, a Washington, D.C.-area private investment firm specializing in government regulated industries, successfully closed its latest fund, Arlington Capital Partners VI (“Fund VI” or the “Fund”). Fund VI closed at its hard cap with total capital commitments of $3.8 billion, exceeding its $3.25 billion target. The Fund was significantly oversubscribed and is the largest in Arlington’s 25-year history.

With the closing of Fund VI, Arlington remains committed to its founding thesis of investing in and growing leading companies in the aerospace and defense, government services and technology, and healthcare sectors that are at the forefront of industrial advancement – from developing next generation national security technologies to creating supply chain resiliency and supporting medical advancements. These companies provide mission-critical products and services that save lives, improve effectiveness, and reduce costs for Department of Defense and Intelligence Community customers; other federal, state, and local government agencies; commercial aerospace companies; and the healthcare industry.

Arlington’s Managing Partners, Matt Altman, Michael Lustbader, Peter Manos, and David Wodlinger, issued the following statement: “The success of this fundraise is a testament to our team’s unrivaled domain expertise, collaborative approach, and consistent track record across our target sectors, which are poised for substantial growth over the next decade-plus. We are tremendously grateful to our investors, and we look forward to putting this capital to work as a partner of choice for founders and management teams, helping to build their businesses into market leaders and sought-after strategic assets.”

Arlington has completed more than 150 investments in its history. To date, Fund VI has already completed eight platform investments and ten follow-on acquisitions, partnering with founders and management teams to build ultra-complex aerospace engine components, fabricate submarine structures for the Navy, develop next generation cyber solutions, manufacture advanced biomaterials and cutting-edge therapeutics, modernize public sector software solutions, and address other critical needs within regulated markets.

Evercore acted as Arlington’s exclusive global placement agent, and Kirkland & Ellis, LLP served as fund counsel.